Very frustrating. Tax returns are going to get much more complicated.
This is the third biotech in the last few months to do this.
BNO and IHL being the others.
They better be confident that some stellar clinical results are on the horizon. Otherwise KZIA will get lost and forgotten in the sea of NASDAQ listed biotechs - more than 20% of which trade below cash backing!